Illuminating Underground Communications Between Plants and Bacteria

Beneficial soil microbes could replace some of the fertilizers and pesticides that are often over-applied. But microbes are motile: they can spread beyond the target crop, where their benefits are diluted or could even cause unintended ecological change. A research team at Stanford and the University of Delaware set out to solve this issue of non-specificity by with a more directed approach by engineering bacteria to “switch on” only near a specific, engineered plant1. We explore this exciting story here.

image of soil in front of a green background. Soil has icons hovering over it - icons for water, sunlight, bacteria, temperature.
Soil, manure and sawdust are stacked in the middle of the green nature.

Building a Private Channel Between a Plant and a Bacterium

The targeted approach this research team wanted to test has three parts: a signal molecule, a plant that sends the signal, and a group of soil bacteria that receive it. The signal is a single molecule, O-methyl-L-tyrosine (OMY). OMY is a noncanonical amino acid, meaning it falls outside the 20 standard amino acids cells use to build proteins. Notably, OMY has not been detected in agricultural soils, which makes it a good candidate for a signal that soil microbes won’t mistake for something else.

The scientists then needed a way to send the signal out through the plant’s roots. To do this, they chose Arabidopsis thaliana, a small, fast-growing flowering plant in the mustard family that researchers widely use as a model in plant biology. They added the gene for a single enzyme, MfnG, to the plant’s genome. MfnG converts the common amino acid tyrosine into OMY. They found that Arabidopsis seedlings grown in a nutrient solution released about 3.1 µM OMY into the liquid around their roots. The plant was ready to deliver the signal. Finally, the researchers needed a species to receive the signal and close the loop. Bacillus subtilis, a common model soil bacterium, was a natural choice because it is well characterized and has established tools for genetic engineering2.

Finally, soil bacteria don’t typically respond to OMY, so the team had to engineer them to. They added genetic components that let B. subtilis incorporate OMY into a protein at an “amber” stop codon, a three-letter genetic signal that normally tells the cell to end a protein at that spot. The team placed this codon in a target gene. Without OMY, protein production halts at the codon. With OMY, the cell reads through it and makes the full-length protein.

Switching the Reporter: From Fluorescence to NanoLuc® Luciferase

With a sender and a receiver in place, the team needed a way to see the conversation. The target gene could be any gene, so they chose a reporter gene, one whose protein produces a measurable signal, so the bacteria would signal only when OMY was present. The question was which reporter would be sensitive enough to detect the small amounts of OMY a plant releases?

The team first used the fluorescent protein mNeonGreen (commercially avaialble, but see this paper for the original research3) as the reporter. mNeonGreen responded to OMY in a dose-dependent way, with 2-fold induction at 1 µM and 20-fold at 1 mM, but the cells also glowed substantially without OMY because translation did not always stop at the single stop codon. To reduce background and widen the dynamic range, they switched to NanoLuc® Luciferase and tested reporters with one or two amber stop codons. Luminescence in the presence of OMY was similar across the variants, but the second stop codon cut background about 55-fold, giving a 3,100-fold change between bacterial cultures with and without OMY. That result reflects NanoLuc® Luciferase and the stop-codon design together, not the enzyme alone.

Next, they tested whether plant-made OMY could switch on the reporter. Arabidopsis seedlings were placed on an agar matrix containing the bacteria and imaged after four days. Luminescence appeared at the roots of OMY-producing plants, about 3.2-fold above the surrounding baseline, compared with 1.4-fold for wild-type plants. When engineered and wild-type seedlings grew side by side, the light concentrated around the engineered ones. A control reporter that doesn’t depend on OMY glowed across the entire plate regardless of plant genotype, so the pattern reflects the OMY signal rather than a plate artifact.

The approach also worked in tomato and poplar roots and in a wild root-colonizing strain of B. subtilis, which needed a different number of stop codons than the lab strain. The same lesson applies to anyone designing a reporter: a sensitive, low-background readout determines what you can detect, and reporter design is worth testing in each system. This is proof-of-concept work, and testing in non-sterile soil with diverse native microbes remains future work. Together, these results are exciting for researchers looking to uncover underground traits in soil communities.

Read the full paper in Nature Biotechnology.

Learn more about NanoLuc® Luciferase here.

References

  1. Zhong, V., Jones, M. A., Cabales, A., Gevorgyan, A., Inckemann, R., Johnson, A. A., Karunadasa, S. S., Forti, A. M., Xu, S.-L., Kunjapur, A. M., & Brophy, J. A. N. (2026). Genetic code expansion enables plant-directed control of bacterial activity. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03360-5 ↩︎
  2. Kang, S.-Y., Pokhrel, A., Bratsch, S., Benson, J. J., Seo, S.-O., Quin, M. B., Aksan, A., & Schmidt-Dannert, C. (2021). Engineering Bacillus subtilis for the formation of a durable living biocomposite material. Nature Communications, 12, Article 7133. https://doi.org/10.1038/s41467-021-27467-2 ↩︎
  3. Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J., Baird, M. A., Sell, B. R., Allen, J. R., Day, R. N., Israelsson, M., Davidson, M. W., & Wang, J. (2013). A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nature Methods, 10(5), 407–409. https://doi.org/10.1038/nmeth.2413 ↩︎

There’s a Fork in DNA Replication, and Pol Theta Takes It

In March 2026, a paper in Molecular Cell revised the understanding of a cancer target whose inhibitors are already being tested in patients. That target is Pol theta, an enzyme nearly every cell has, there to patch breaks in damaged DNA. This repair job has made it a clinical-stage drug target for years: cells that can’t repair their DNA tend to die, and cancer cells, which rack up far more damage than normal cells, are especially vulnerable to losing that option. That’s the kind of established model a field builds whole drug programs on.

Those programs include trials enrolling patients right now, testing Pol theta inhibitors in BRCA-mutant tumors and others that have lost homologous recombination (HR), a different, generally more reliable way of repairing broken DNA than the one Pol theta handles. Losing HR alone doesn’t kill these tumor cells, since they still have Pol theta’s pathway to fall back on. Take that away too, and a cancer cell that’s already down to one option for fixing this kind of damage also loses its last chance of surviving it. Scientists call this synthetic lethality.

This year, two independent labs, researching different questions, found that Pol theta plays a different role than assumed.

Continue reading “There’s a Fork in DNA Replication, and Pol Theta Takes It”

Same Symptoms, Different Parasite: Cyclospora and Cryptosporidium Up Close

Cryptosporidum up close

Cyclospora and Cryptosporidium are easy to confuse. The names nearly rhyme, the illnesses look alike and both slip past routine stool tests; however, the resemblance mostly ends there.

Cryptosporidium is far more common, causing an estimated 800,000+ US illnesses a year, often spread through contaminated water (1). Cyclospora is typically rarer, with lab-confirmed US cases totaling 1,180 between May and August 2025, but over the same window in 2026, fueled in part by a lettuce-linked outbreak, that count neared 20,000 (2).

So if they seem so alike, what actually separates the two?

Continue reading “Same Symptoms, Different Parasite: Cyclospora and Cryptosporidium Up Close”

Simplifying Protein Purification with HaloTag® Technology

Introduction

artists view inside a cell

Detecting and isolating proteins is challenging when they’re expressed at low native abundance, lack good antibodies, or localize to complex subcellular compartments. Promega developed HaloTag® technology to address these challenges. The system is quite simple. A HaloTag® protein fusion tag is added to your protein of interest, which can be paired with one of many interchangeable ligands to form a highly specific covalent bond. The range of synthetic ligands includes chemical probes, affinity handles, and fluorescent dyes.

Beyond the ligand binding, HaloTag itself functions as a powerful foothold for protein isolation studies. The Magne® HaloTag® Beads enable magnetic capture and isolation of a protein of interest with minimal non-specific binding, supporting clean downstream pull-downs and purification.
Below I highlight an exciting publication that demonstrates the power of HaloTag in enriching phosphotyrosine peptides, a classically challenging area of proteomics.

Continue reading “Simplifying Protein Purification with HaloTag® Technology”

Invisible Leishmaniasis: How a One Health Approach Changed Everything in Honduras

Imagine a parasite circulating actively in a community, infecting dogs, spreading through insect vectors, moving between multiple species—and no one notices. Not because people aren’t looking, but because traditional disease surveillance only watches clinical cases in humans, missing the invisible circulation happening all around them. Research on emerging zoonotic diseases confirms this dynamic is not unique to Honduras, it reflects a global risk intensified by urbanization and climate change. Read more about this in our Promega Connections blog (2).

Continue reading “Invisible Leishmaniasis: How a One Health Approach Changed Everything in Honduras”

Ancient Proteins Reveal Mysterious Human Relatives in Southwestern China

Denisovans are one of the most elusive branches of the human family tree. Scientists first identified them in 2010, when DNA from a tiny finger bone found in Denisova Cave in Siberia revealed a previously unknown group of ancient humans. Since then, researchers have confirmed only a handful of fossils outside Siberia as Denisovan—two jaws, a rib and a skull.

However, genetic evidence suggests Denisovans traveled widely. People in Southeast Asia and Oceania still carry Denisovan DNA. What was missing was fossil evidence from the region in between: southwestern China. Now, a new study published in Nature could fill that gap.

Continue reading “Ancient Proteins Reveal Mysterious Human Relatives in Southwestern China”

The Template That Stayed Behind: Why DNA Removal After In Vitro Transcription Is Harder Than It Looks

In Vitro Transcription

Every in vitro transcription (IVT) reaction starts with DNA you put there on purpose. A linearized plasmid or polymerase chain reaction (PCR) template goes in, the polymerase does its work and a few hours later you have RNA, often a lot of it. The template’s job is done.

In theory, a quick DNase step takes care of the rest.

In practice, the template doesn’t always leave quietly.

The DNA you added is the hardest DNA to remove

In an IVT reaction, the DNA was added deliberately, often in microgram amounts. It sits in a buffer designed to make the polymerase as productive as possible, which is not the same as making DNase productive.

That’s the trade-off at the center of IVT cleanup. The easiest place to digest the template is the reaction tube, right after transcription, with no extra purification step. But IVT reactions carry high ionic strength and a crowded mix of other components, conditions that suppress the activity of many DNase I enzymes (1,2). The reaction is good at making RNA and bad at getting rid of what made it.

Continue reading “The Template That Stayed Behind: Why DNA Removal After In Vitro Transcription Is Harder Than It Looks”

Adapting a Cell-Based Immunoassay for HTS: From the Bench to a 7,000-Compound Screen 

High-throughput screening (HTS) has been a central approach in small-molecule drug discovery since the late 1980s. It gives researchers a systematic way to find hits: compounds that act on a target and can be refined into drug candidates. The assays used in those screens matter, and cell-based assays are especially valuable because they bridge biochemical assays and in vivo models. Biochemical assays give direct readouts but miss the cellular context, while in vivo models are informative, but costly and slow. Cell-based assays enable scientists to study signaling pathways, target modulation and cytotoxicity in a more native environment, at a practical scale. 

image of puprle and blue antibodies coming together to form a luminescent compelx (lumit assay)

Many cell-based screens depend on engineered reporter systems: cells genetically modified so a pathway of interest produces a measurable signal, such as light or fluorescence. These cell lines take significant time and effort to build and maintain, and because they’re modified, they may not reflect disease-relevant cell states. As drug discovery moves toward primary cells and patient-derived lines, assays that detect endogenous proteins without genetic manipulation become more appealing. Those assays work across more cell types and are faster to set up. 

Continue reading “Adapting a Cell-Based Immunoassay for HTS: From the Bench to a 7,000-Compound Screen “

Where Science Meets Art: 30 Years of the Promega Art Showcase

On September 17, 2026, the Promega Art Showcase opened its fall exhibition, the 14th PhotoMidwest Biennial Juried Exhibition. Sixty-five photographs by photographers in 13 Midwestern states are on display in the Promega BioPharmaceutical Technology Center (BTC).

This exhibition opening marked another notable occasion – the Promega Art Showcase is honoring its 30th anniversary. Since 1996, Promega has hosted the showcase to celebrate the intersection of art and science. Dozens of professional artists have displayed their work at Promega, connecting Promega employees and the Madison-area community with exhibits exploring the human condition.

Continue reading “Where Science Meets Art: 30 Years of the Promega Art Showcase”

Nitrile Gloves, Not Ribbons

Every October, the noise starts up again: it’s breast cancer’s turn for awareness. I brace for it a little every year. What bothers me isn’t the concept, it’s watching companies race to out-pink each other.

A pink ribbon on a shirt or a car can foster a certain amount of solidarity, but at the corporate level, the awareness noise is genuinely inescapable: a building lit up pink for the night, a pink yogurt lid, or a player running out onto the field in pink cleats. Many companies have run some version of the same campaign, and what actually happens to the profit from pink merchandise varies wildly: modest percentages, hard caps on total donations, or numbers that only recently moved after enough people asked questions.

In addition to the question of money is the question of effect: what does a company’s participation do? If the goal actually is awareness, I’ve never understood who remains unaware. It tends to generate goodwill instead, and the sometimes cynical among us might call that marketing, whether or not that’s the intent.

Here’s a sentence that’s true to me, one most people have their own version of: my sister had breast cancer. One in eight women in the U.S. will hear that diagnosis in her lifetime (though women aren’t the only ones who get it). So we are aware. We have been aware for a long time.

At one point, however, we actually needed awareness, in the literal sense of the word. When the American Cancer Society started its breast cancer awareness campaign in 1985, breast cancer was a disease people didn’t discuss in polite company, self-exams weren’t routine, and mammograms weren’t the norm they are now. Getting people to talk about it, check themselves, and get screened was a real, specific goal, and awareness did its job at the time. Last year marked the campaign’s fortieth anniversary, a point at which even the American Cancer Society’s own retrospective pointedly admitted: awareness alone isn’t enough anymore.

October runs on that word, awareness, as if noticing something were the same as solving it. As if on November 1st, we can dust off our hands, congratulate ourselves, and move on to the next color of the month. But breast cancer research doesn’t run on that calendar. Real, promising work has been happening. Learning about it might not change anything either, not directly, but it’s one step closer to what the American Cancer Society itself is now calling “Turning Awareness Into Action.”

More Than a Pretty Face

This starts, perhaps unexpectedly, with the axolotl, a foot-long Mexican salamander known for its perpetual smile and the feathery gills that fan out from its head like a spray of coral. The most common pet-store variety is also, conveniently for this piece, pale pink. It has become plastered across backpacks, folders, plush toys, and t-shirts. My nine-year-old niece and her friends are obsessed with them.

Continue reading “Nitrile Gloves, Not Ribbons”